mProX™ Human MAPK9 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1180	Magic™ Human JNK2(MAPK9) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

MAPK9

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

G62; G91; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Digestive and Renal Research; Cancer Research

Related Diseases

Breast Cancer and Kidney Disease. Among its related pathways are MyD88 dependent cascade initiated on endosome and Prolactin Signaling

Gene ID

5601

UniProt ID

P45984

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The MAPK9 gene in humans encodes the enzyme mitogen-activated protein kinase 9. This gene codes for a protein that belongs to the family of MAP kinases. This kinase facilitates immediate-early gene expression in response to different cell stimuli by targeting particular transcription factors. It shares the greatest degree of similarity with MAPK8, since both are involved in UV radiation-induced apoptosis, which is believed to be connected to the route of cytochrome c-mediated cell death. MAPK8 and this gene are also referred to as c-Jun N-terminal kinases. This kinase promotes the stability of tumor suppressor p53 in non-stressed cells by preventing its ubiquitination. Research on the mouse equivalent of this gene points to a crucial function in T-cell development. The customized MAPK9 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Nancy

The MAPK9 cell line is an excellent product that has exceeded my expectations. Feb 21 2022

chat Verified Customer

chat David

The MAPK9 KD cell line is easy to use, and the results obtained have been consistent and reliable. Oct 31 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Overexpression of MAPK9 increases glioma cell proliferation and migration.

Western blotting was used to confirm that the cell transfection procedure was successful. The shMAPK9 group's MAPK9 expression level was noticeably lower than that of the control group. The MAPK9 overexpressing cells had much higher levels of MAPK9 expression than the control cells did.

Ref: Yang, Xinyu, et al. "MAPK9 is Correlated with a Poor Prognosis and Tumor Progression in Glioma." Frontiers in Bioscience-Landmark 28.3 (2023): 63.

Pubmed: 37005756

DOI: 10.31083/j.fbl2803063

Research Highlights

Compared to paraneoplastic tissues, glioma tissues expressed more MAPK9. The MAPK9 expression level is an independent prognostic factor in glioma patients, according to prognostic and survival assessments.
Yang, Xinyu, et al. "MAPK9 is Correlated with a Poor Prognosis and Tumor Progression in Glioma." Frontiers in Bioscience-Landmark 28.3 (2023): 63.
Pubmed: 37005756 DOI: 10.31083/j.fbl2803063

In NSCLC instances, there is an upregulation of CircRNF20 and MAPK9, which is closely associated with T stage in NSCLC patients. They function as separate NSCLC prognostic factors. CircRNF20 enhances NSCLC growth by activating MAPK9.
Wang, Z-X., et al. "CircRNF20 aggravates the progression of non-small-cell lung carcinoma by activating MAPK9." European Review for Medical & Pharmacological Sciences 24.19 (2020).
Pubmed: 33090403 DOI: 10.26355/eurrev_202010_23211